For cancer immunotherapy, T-cell immunoglobulin and TIGIT, as well as CTLA-4, PD-1, T-cell immunoglobulin 3 and lymphocyte activation gene 3, are the most commonly targeted checkpoints [26]. Here, CTLA4 is linked to cancer.